Gene editing has struggled to go commercial. This Nobel laureate has a $1 billion plan to fix that
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mainstream.